- Home
- SRPT vs MRK Comparison
SRPT vs MRK Comparison
Compare SRPT & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRPT
- MRK
- Stock Information
- Founded
- SRPT 1980
- MRK 2000
- Country
- SRPT United States
- MRK United States
- Employees
- SRPT N/A
- MRK N/A
- Industry
- SRPT Biotechnology: Pharmaceutical Preparations
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- SRPT Health Care
- MRK Health Care
- Exchange
- SRPT Nasdaq
- MRK Nasdaq
- Market Cap
- SRPT 1.9B
- MRK 218.8B
- IPO Year
- SRPT 1997
- MRK N/A
- Fundamental
- Price
- SRPT $22.20
- MRK $84.12
- Analyst Decision
- SRPT Hold
- MRK Buy
- Analyst Count
- SRPT 31
- MRK 15
- Target Price
- SRPT $40.61
- MRK $105.14
- AVG Volume (30 Days)
- SRPT 6.2M
- MRK 13.5M
- Earning Date
- SRPT 11-05-2025
- MRK 10-30-2025
- Dividend Yield
- SRPT N/A
- MRK 3.85%
- EPS Growth
- SRPT N/A
- MRK 20.41
- EPS
- SRPT N/A
- MRK 6.49
- Revenue
- SRPT $2,481,531,000.00
- MRK $63,616,000,000.00
- Revenue This Year
- SRPT $9.41
- MRK $1.84
- Revenue Next Year
- SRPT N/A
- MRK $5.24
- P/E Ratio
- SRPT N/A
- MRK $12.97
- Revenue Growth
- SRPT 64.89
- MRK 1.82
- 52 Week Low
- SRPT $10.42
- MRK $73.31
- 52 Week High
- SRPT $138.81
- MRK $111.58
- Technical
- Relative Strength Index (RSI)
- SRPT 58.71
- MRK 48.59
- Support Level
- SRPT $20.92
- MRK $86.20
- Resistance Level
- SRPT $25.32
- MRK $88.24
- Average True Range (ATR)
- SRPT 1.38
- MRK 2.23
- MACD
- SRPT 0.12
- MRK -0.09
- Stochastic Oscillator
- SRPT 59.35
- MRK 48.29
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).